Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Exclusion Criteria

• •Have an increased risk of osteosarcoma (bone tumor); this includes Paget's disease of bone, a previous bone tumor, or radiation involving the skeleton
• •Are allergic or cannot tolerate teriparatide or zoledronic acid or any of their ingredients or components
• •Are allergic to tetracycline
• •Have a history of exposure to tetracycline therapy in the 3 months prior to trial entry
• •Have participated in a prior PTH clinical trial or received prior treatment with teriparatide, PTH, or other related medications
• •Have a vitamin D level below 10 nanogram/milliliter (ng/mL)
• •Have a condition that could possibly put one at risk for an adverse event due to the bone biopsy procedure (e.g. bleeding disorder)
• •Have undergone two previous iliac crest bone biopsies (one in each iliac crest)
• •Have taken any intravenous (IV) osteoporosis medication
• •Have taken other oral osteoporosis medications and have not been off of them for a specific period of time before trial entry
• •Have a history of certain cancers in the 5 years prior to trial entry
• •Have active liver disease
• •Have significantly impaired kidney function
• •Currently have active or suspected diseases that affect the bones, other than osteoporosis
• •Have active or recent history of significant gastrointestinal (stomach or intestinal) disorders
• •Have been treated with certain glucocorticoids for more than 30 days in the past 1 year prior to trial entry